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Abstract
To investigate whether hemoglobin, white blood cell count (WBC), urea, sodium, albumin, and C-reactive protein at discharge in
patients hospitalized for community-acquired pneumonia (CAP) are associated with 30-day readmission. This study is a retro-
spective cohort study, which included all adult patients discharged after hospitalization for CAP from three Danish hospitals
between January 2011 and July 2012. The outcome was all-cause, unplanned, 30-day readmission. Biomarker concentrations at
discharge were transformed into binary variables by using either upper or lower quartiles as cut-off; the upper quartile was used
for WBC, urea, and C-reactive protein, and the lower quartile was used for hemoglobin, sodium, and albumin. The study
population consisted of 1149 patients. One hundred eighty-four (16.0%) patients were readmitted. Independent risk factors of
readmission wereWBC ≥ 10.6 cells × 109/L (hazard ratio 1.50; 95%CI, 1.07–2.11) and albumin <32 g/L (hazard ratio 1.78; 95%
CI, 1.24–2.54) at discharge and the presence of ≥ 2 co-morbidities (hazard ratio 1.74; 95% CI, 1.15–2.64).WhenWBC, albumin,
and co-morbidities were combined into a risk-stratification tool, there was a step-wise increase in risk of readmission for patients
with 1, 2, or 3 risk factors with hazard ratios of 1.76 (95% CI, 1.25–2.49), 2.59 (95% CI, 1.71–3.93), and 6.15 (95% CI 3.33–
11.38), respectively. WBC ≥ 10.6 cells × 109/L and albumin < 32 g/L at discharge and the presence of ≥ 2 co-morbidities were
independently associated with increased risk of 30-day readmission.
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Introduction
Community-acquired pneumonia (CAP) is a common cause
of hospitalization, and with as many as 1 in 5 patients
returning to the hospital within 30 days after discharge, read-
mission is a significant burden to both patients and healthcare
systems [1–4].
Readmission may be prevented with post-discharge inter-
ventions, but success and cost-effectiveness partly depend on
accurate risk-stratification, which again presupposes identifi-
cation of important risk factors [5, 6]. Risk factors of readmis-
sion for patients hospitalized for CAP have not been well
described, and previous research has primarily evaluated fac-
tors which either pre-exist the pneumonia or reflect the sever-
ity at the day of admission [7–12]. Factors, which reflect the
cause of hospitalization and the health status at discharge,
might, however, be important predictors of readmission [13].
We hypothesized that six different blood-based biomarkers
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routinely measured in patients with CAP would be associated
with risk of readmission after hospitalization for CAP and
could be used in a risk-stratification tool.
Thus, the objective of this study was to investigate whether
hemoglobin, white blood cell count (WBC), urea, sodium,
albumin, and C-reactive protein at discharge in patients hos-
pitalized for CAP are associated with 30-day readmission.
Methods
Setting and patients
This study was based on the retrospective CAP-NORTH
Cohort, which has previously been described in detail by
Egelund et al. [14]. In brief, the CAP-NORTH Cohort was
created by evaluating all consecutive patients with an ICD-10
code of pneumonia admitted to three Danish hospitals between
January 1, 2011, and July 1, 2012. The inclusion criteria were a
new pulmonary infiltrate on chest radiography in combination
with at least one symptom of lower respiratory tract infection at
admission. Patients with HIV, active tuberculosis, or pharma-
cological immunosuppression or patients who had been hospi-
talized within the preceding 28 days of admission were exclud-
ed. Patients with more than one admission during the study
period were included with reference to the first contact.
In this study, patients who died during the index-
hospitalization or had missing data on follow-up or bio-
markers at discharge were excluded.
Variables
Information on demographic characteristics, co-morbidities,
initial severity of the pneumonia, and the course of index-
hospitalization was collected from medical records. The fol-
lowing co-morbidities were registered: chronic obstructive re-
spiratory disease (COPD), other chronic respiratory diseases,
malignancy, chronic heart failure, other chronic heart diseases,
neurovascular diseases, other chronic neurological diseases,
chronic renal failure, chronic liver failure, and diabetes. The
combined burden of co-morbidities was assessed by catego-
rizing patients into three groups based on the sum of condi-
tions (none, one, and more than one). The severity of the
pneumonia was measured by the CURB-65 score, which is a
composite risk-stratification tool that predicts 30-day mortal-
ity in patients with CAP [15].
Biomarkers at discharge were defined as the last available
measurement before discharge during the index-hospitaliza-
tion. In cases with more than one measurement on the same
day, the highest value was used. Collection and analysis of
blood samples was part of the in-hospital routine management
of patients.
Variables that were not mentioned in medical records were
recorded as missing. All data were entered into the CAPNETZ
database (www.capnetz.de) or into a database programmed in
EpiData entry 3.1 (www.epidata.dk). Both databases had
error-detection features.
Outcomes
The outcome measure was all-cause, unplanned readmission
within 30 days after discharge from the index-hospitalization.
The days from discharge to readmission and the cause of
readmission were registered. Further, it was registered if pa-
tients died in the follow-up period without a preceding read-
mission. Patients with multiple readmissions were registered
with reference to the first readmission. Data on outcome were
collected from medical records, which via linkages to The
Danish National Patient Register and The Danish Civil
Registration System hold information on all public hospitali-
zations and mortality [16].
Statistical analyses
As all continuous variables were skewed, median and inter-
quartile range (IQR) was reported. Differences in median
values were tested by the non-parametric Wilcoxon rank-
sum test. Counts and percentages were reported for categorical
variables. Differences between categorical variables were test-
ed with Person’s test or Fisher’s exact test, as appropriate.
To account for competing risk in form of death without a
preceding readmission, a regression model proposed by Fine
and Gray [17] was used to calculate sub-distributed hazard
ratios for variables based on the cumulative incidence function
of readmissions. Data was censored at 30 days after discharge.
In the regression analyses, biomarkers were evaluated as bi-
nary variables: quartiles for biomarker concentrations were
calculated, and for WBC, urea, and C-reactive protein, the
upper quartile was used as cut-off, while the lower quartile
was used as cut-off for hemoglobin, sodium, and albumin.
Variables with p < 0.1 in the univariate analyses were included
in the multivariate analysis. A risk-stratification tool was de-
rived by dividing patients into groups based on the summa-
rized number of independent risk factors of readmission.
Corresponding cumulative incidence curves and hazard ratios
were generated.
Two sensitivity analyses were performed: In the first sen-
sitivity analysis, the variable assessing the combined burden
of co-morbidities was replaced with individual co-morbidities
in the multivariate analysis. In the second sensitivity analysis,
the multivariate analysis was restricted to patients, who had a
valid measurement of biomarkers within 3 days of discharge.
All p values were two-sided and significance levels were <
0.05. All analyses were performed in SAS Enterprise Guide 7.1.
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Data availability The datasets generated and analyzed during
the current study are available from the corresponding author
on reasonable request.
Results
Study population
Of the 1320 patients in the CAP-NORTH Cohort, 111 (8.4%)
died during the initial hospitalization, 8 (0.6%) were lost to
follow-up, and 52 (3.9%) had missing data on biomarkers at
discharge (Fig. 1) [12]. These patients were excluded. Thus,
the total study population consisted of 1149 patients, who
were discharged alive. Patients who were excluded due to
missing data on biomarkers were hospitalized and received
intravenous (I.V.) antibiotics for a shorter period than the
study population (median length of I.V. antibiotic treatment
1 day (IQR, 0–3) vs. 3 days (IQR, 2–6), p < 0.001 and median
length of stay 1.5 days (IQR, 1–4.5) vs. 5 days (IQR, 3–9),
p < 0.001). No other differences in baseline characteristics or
outcomes were observed (Appendix, Table 1).
Baseline characteristics
The median age of the study population was 70 years (IQR, 57–
81), 40.6% had no record of co-morbidities, 35.7% had 1 co-
morbidity, and 23.7% had ≥ 2 (Table 1). Based on the CURB-65
score, 15.7% of the patients had a severe pneumonia at admis-
sion (more than 2 points). The median length of stay of the
index-hospitalization was 5 days (IQR, 3–9), and the median
length of treatment with I.V. antibiotics was 3 days (IQR, 2–6).
Among 952 patients, where a microbiological test was per-
formed, 217 (22.8%) had a pathogen detected (Table 2). The
two most common pathogens were Streptococcus
pneumoniae (n = 61, 6.4%) and Haemophilus influenzae
(n = 55, 5.8%).
Outcomes
One hundred eighty-four (16.0%) patients were readmitted
within 30 days after discharge and 27 (2.3%) died without a
preceding readmission. A total of 56 (4.9%) patients died
within the 30-day follow-up period. Pneumonia was the most
common cause of readmission accounting for 35.2% of all
readmissions (Table 3). Other frequent causes of readmission
were pulmonary and cardiovascular diseases, which
accounted for 12.5 and 12.0%, respectively.
Biomarker concentrations at discharge
Patients who were readmitted had higher medianWBC concen-
trations (9.4 vs 8.4 cells × 109/L, p < 0.001) and median urea
concentrations (5.4 vs. 4.6 mmol/L, p = 0.001) and lower
Died before discharge
(111)
Lost to follow-up
(8)
Study population
(1149)
Readmitted
(184)
CAP-NORTH Cohort
(1320)
Died without 
readmission
(27)
Alive without 
readmission
(938)
Missing values at discharge
(52)
Fig. 1 Flow chart of the study
population
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median albumin concentrations (35 vs 36 g/L, p < 0.001) than
patients who were not readmitted (Table 4). Patients were divid-
ed into binary groups based on biomarker concentrations, with
cut-offs corresponding to the upper quartile for WBC, urea, and
C-reactive protein and the lower quartile for hemoglobin, sodi-
um, and albumin. Quartile-based cut-offs were hemoglobin <
7.0 mmol/L, WBC ≥ 10.6 cells × 109/L, urea ≥ 7.0 mmol/L, so-
dium < 137 mmol/L, albumin < 32 g/L, and CRP ≥ 70 mg/L.
Risk factors of readmission
In the univariate analyses WBC, urea, and albumin were sig-
nificantly associated with readmission (Table 5). Hazard ratios
were 1.67; 95% CI, 1.23–2.25 for patients with WBC ≥
10.6 cells × 109/L or urea ≥ 7.0 mmol/L. For patients with
albumin < 32 g/L, the hazard ratio was 1.74; 95% CI, 1.28–
2.36. Cumulative incidence curves of biomarkers are plotted
in Fig. 2.
In the multivariate analysis, the associations remained sig-
nificant forWBC and albumin with hazard ratios of 1.50; 95%
CI, 1.07–2.11 and 1.78; 95% CI, 1.24–2.54, respectively
(Table 5). The only baseline characteristic that was indepen-
dently associated with readmissions was the combined burden
of co-morbidities. The hazard ratio was 1.74; 95% CI, 1.15–
2.64 for patients with ≥ 2 co-morbidities compared to patients
without co-morbidities.
In order to identify a combined risk-stratification tool, we
assessed the combined risk of all independent risk factors.
Figure 3 shows the cumulative incidence curves of 0, 1, 2,
and 3 risk factors. The corresponding hazard ratios, where
patients without risk factors served as the reference group
(n = 509), were 1.76, 95% CI, 1.25–2.49 for patients with 1
risk factor (n = 454); 2.59, 95% CI, 1.71–3.93 for patients
with 2 risk factors (n = 149); and 6.15, 95% CI, 3.33–11.38
for patients with 3 risk factors (n = 27). As 10 patients had
missing data on co-morbidities, the total number of patients
in the four groups summarizes to 1139.
Sensitivity analyses
Replacing the variable assessing the combined burden of co-
morbidities with individual co-morbidities in the multivariate
model did not change the associations between WBC (hazard
ratio 1.53; 95% CI, 1.09–2.16) and albumin (hazard ratio
Table 1 Baseline characteristics of the study population
Baseline characteristic Study
population
(N = 1149)
Demographic factor
Age, year, median (IQR) 70 (57–81)
Sex, male 537 (46.7)
Nursing home residency 110 (9.6)
Active smoker 296 (27.8)
Co-morbidities
Number co-morbidities
0 462 (40.6)
1 407 (35.7)
≥ 2 270 (23.7)
Malignancy 99 (8.6)
COPD 208 (18.3)
Other chronic respiratory disease 138 (12.1)
Chronic heart failure 90 (7.9)
Other chronic heart disease 174 (15.2)
Chronic liver disease 9 (0.8)
Chronic kidney disease 39 (3.4)
Cerebrovascular disease 109 (9.5)
Other chronic neurological disease 44 (3.8)
Diabetes mellitus 142 (12.2)
Severity of pneumonia at admission
CURB-65 score
0–1 559 (55.9)
2 284 (28.4)
3–5 157 (15.7)
Course of hospitalization
Length of I.V. antibiotics, d, median (IQR) 3 (2–6)
Length of stay, day, median (IQR) 5 (3–9)
ICU admittance 80 (7.0)
Other chronic respiratory diseases were asthma, bronchiectasis, pulmo-
nary fibrosis, sarcoidosis, sleep apnea. Chronic cardiac diseases were
cardiac arrhythmia, ischemic heart disease, and cardiomyopathy. Other
chronic neurological diseases were epilepsy, Parkinson’s disease, multi-
ple sclerosis and amyotrophic lateral sclerosis. All variables had less than
1% missing values except CURB-65 score (13.0%) and active smoker
(7.3%). All variables are reported as numbers and percentages unless
otherwise stated
IQR interquartile range, COPD chronic obstructive pulmonary disease,
I.V. intravenous, ICU intensive care unit
Table 2 Etiology by study population and tested population
Pathogen Number Percentage
of study
population
(N = 1149)
Percentage
of tested
population
(N = 952)
Streptococcus pneumoniae 61 5.3 6.4
Haemophilus influenzae 55 4.8 5.8
Mycoplasma pneumoniae 35 3.0 3.7
Moraxella catarrhalis 19 1.7 2.0
Staphylococcus aureus 8 0.7 0.8
Pseudomonas aeruginosa 11 1.0 1.2
Escherichia coli 8 0.7 0.8
Legionella pneumophila 5 0.4 0.5
Others 15 1.3 1.6
Total 217 18.9 22.8
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1.82; 95% CI, 1.28–2.60) and readmission (Appendix,
Table 2). Of note, COPD and other neurological diseases were
significantly associated with readmission (hazard ratios 1.61;
95% CI, 1.12–2.30 and 2.69; 95% CI, 1.49–4.85,
respectively).
The percentages of patients with a measurement of hemo-
globin, WBC, urea, sodium, albumin, and C-reactive protein
within 3 days before discharge were 86.2, 93.6, 85.0, 88.1,
69.7, and 93.4, respectively. No changes of hazard ratios of
WBC (1.78; 95% CI, 1.17–2.72) or albumin (1.87; 95% CI,
1.17–2.98) were observed when the multivariate analysis was
restricted to the subset of patients (n = 754, 65.6%), where all
biomarkers were measured within 3 days before discharge
(Appendix, Table 3).
Discussion
In this retrospective, multi-center, cohort study of 1149 pa-
tients discharged after hospitalization for CAP, we found that
WBC ≥ 10.6 cells × 109/L and albumin < 32 g/L at discharge
and the presence of ≥ 2 co-morbidities are independent risk
factors of 30-day readmission. Further, when WBC, albumin,
and co-morbidities were combined into a risk-stratification
tool, we found a step-wise increase in risk of readmission
according to the number of risk factors.
Previous research on identification of risk factors of read-
mission after hospitalization for CAP is limited and factors
which primarily have been evaluated either pre-exist the pneu-
monia or reflect the severity at the day of admission. Apart
from the presence of co-morbidities, which throughout the
literature are found to be an independent risk factor readmis-
sion, other frequently evaluated factors, such demographic
characteristics and the initial severity of the pneumonia, are
not consistently found to be associated with readmission
[7–12]. To the best of our knowledge, this study is the first
to both evaluate and demonstrate associations between albu-
min and WBC at discharge and readmission after CAP.
Biomarkers at discharge may reflect the health status of pa-
tients during a period of recovery and could provide additional
information on the risk of readmission besides what can be
obtained at the day of admission. Correspondingly, some stud-
ies in different patient populations, have found that risk-
stratification tools of readmission are improved when data
from the entire hospital stay are added to data from the first
day of hospitalization [18, 19]. Length of hospitalization, du-
ration of antibiotic treatment, and signs of clinical instability at
discharge, which also relate to the health status beyond the day
of admission, are, however, not consistently found to be pre-
dictive of readmissions after hospitalization for CAP [7–12].
As elevated WBC and depressed albumin are common
findings during acute infections, our results could reflect that
some patients were discharged too early from the hospital with
an on-going pneumonia. Unfortunately, clinical parameters
beyond the day of admission were not available in the CAP-
NORTH Cohort, and thus, we could not review whether these
patients also had clinical signs of active infection at discharge.
There are, however, some indications that treatment and dis-
charge patterns in our study were not different from other
studies. First, with a median and IQR of WBC at discharge
of 8.6 and 6.9–10.6 cells × 109/L, results from our study was
very similar to results from another study of patients with
Table 3 Causes of
readmission Cause of readmission Number (%)
Pneumonia 65 (35.2)
Pulmonary 23 (12.5)
Cardiovascular 22 (12.0)
Infection 20 (10.9)
Malignant 11 (6.0)
Surgical 8 (4.3)
Neurological 6 (3.3)
Other 29 (15.8)
Total 184 (100)
Table 4 Biomarker
concentrations at discharge Biomarker at discharge All (N = 1149) Not readmitted
a (N = 938) Readmitted (N = 184) p value
Hemoglobin, mmol/L 7.7 (7.0–8.3) 7.7 (7.0–8.3) 7.6 (7.0–8.3) 0.324
WBC, cells × 109/L 8.6 (6.9–10.6) 8.4 (6.7–10.4) 9.4 (7.7–11.8) < 0.001
Urea, mmol/L 4.7 (3.5–7.0) 4.6 (3.4–6.6) 5.4 (3.7–8.3) 0.001
Sodium, mmol/L 139 (137–141) 139 (137–141) 139 (136–141) 0.799
Albumin, g/L 35 (32–39) 36 (32–39) 35 (30–38) < 0.001
C-reactive protein, mg/L 38 (18–70) 38 (18–69) 39 (18–72) 0.973
All variables are reported asmedians and interquartile ranges. p values refer to differences between not readmitted
and readmitted patients
mmol/L millimole per liter, WBC white blood cell count, g/L grams per liter, mg/L milligrams per liter
a The 27 patients who died without a preceding readmission are not included in the group of patients not
readmitted
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CAP, which reported a median and IQR of WBC at discharge
of 8.3 and 6.5–11.0 cells × 109/L. Second, in terms of treat-
ment, both the length of hospitalization and the duration of
I.V. antibiotic therapy in our study were within international
recommendations for treatment of CAP [20]. And third, the
outcome in our study, both as the overall readmission rate and
the proportion of readmissions caused by pneumonia, were
similar to reports from other studies, which would not be
expected if patients were discharged too early with an on-
going pneumonia [7–12, 21].
Elevated WBC at discharge could also reflect persistent
inflammation rather than active infection. In a study from
2008, Yende et al. [22] reported that high discharge concentra-
tions of the pro-inflammatory marker IL-6 were associated
with an increased risk of mortality 3 months after hospitaliza-
tion for CAP. As the authors also suggested, one possible
mechanism could be that a persistent inflammation after acute
infections increases the risk of cardiovascular events in the
same way as elevated levels of inflammatory markers increase
the risk in other populations [23].
In 2013, Krumholz [24] proposed that stressors occurring
during hospitalization, such as malnutrition, sleep deprivation,
and immobility, increase the vulnerability of patients after
discharge, a phenomenon described as a post-hospital
syndrome. These factors, and not only pre-existing conditions
or the severity of the disease at the day of admission, may
significantly affect the risk of readmission. Biomarkers mea-
sured at discharge might pose a simple and reliable way to
assess some of the impact that hospitalization has on the health
status of the patients, and thus be useful in identification of
patients in high risk of readmission.
When WBC, albumin, and co-morbidities are combined
into a risk-stratification tool, the study population could be
divided into four groups with a step-wise increase in risk of
readmission. This suggests that the combination of bio-
markers at discharge and co-morbidities could be used to iden-
tify patients which are in need of post-discharge interventions.
There are, however, need for validation in prospective studies.
Limitations
Our study had some limitations. First, due to the retrospective
design of the study, the measurement of biomarkers was part
of the routine management of patients. This could have led to
Table 5 Risk factors of
readmission Variable Unadjusted hazard
ratios (95% Cl)
p value Adjusted hazard
ratios* (95% Cl)
p value
Biomarker at discharge
Hemoglobin, < 7.0 mmol/L 1.12 (0.80–1.56) 0.511 – –
WBC, ≥ 10.6 cells × 109/L 1.67 (1.23–2.25) < 0.001 1.50 (1.07–2.11) 0.018
Urea, > 7.0 mmol/L 1.67 (1.23–2.25) < 0.001 1.09 (0.75–1.59) 0.660
Sodium, < 137 mmol/L 1.28 (0.93–1.76) 0.137 – –
Albumin, < 32 g/L 1.74 (1.28–2.36) < 0.001 1.78 (1.24–2.54) 0.002
C-reactive protein, ≥ 70 mg/L 1.06 (0.76–1.48) 0.717 – –
Baseline characteristic
Age, per year 1.02 (1.01–1.03) < 0.001 1.01 (1.00–1.02) 0.128
Sex, male 1.40 (1.05–1.87) 0.022 1.28 (0.93–1.77) 0.135
Nursing home residency 1.55 (1.02–2.34) 0.041 1.27 (0.76–2.14) 0.360
Active smoker 0.96 (0.69–1.33) 0.794 – –
Number co-morbidities
0, reference
1 1.12 (0.78–1.61) 0.549 1.03 (0.69–1.56) 0.875
≥ 2 2.09 (1.48–2.96) < 0.001 1.74 (1.15–2.64) 0.009
CURB-65 score
0–1, reference
2 2.27 (1.60–3.23) < 0.001 1.44 (0.94–2.20) 0.091
3–5 2.20 (1.44–3.36) < 0.001 1.22 (0.72–2.06) 0.452
Length of I.V. antibiotics, per day 1.03 (1.00–1.05) 0.026 0.99 (0.94–1.04) 0.661
Length of stay, per day 1.02 (1.01–1.03) 0.005 1.02 (0.99–1.04) 0.350
ICU admittance 0.68 (0.35–1.34) 0.266 – –
mmol/L millimole per liter, WBC white blood cell count, g/L grams per liter, mg/L milligrams per liter, I.V.
intravenous, ICU intensive care unit
a Due to missing values, a total of 938 patients were used in the multivariate model
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a selection bias, as 52 patients was excluded due to missing
values, and thus, our findings may not be generalized to all
patients hospitalized for CAP. The 52 patients who were ex-
cluded were hospitalized and received I.V. antibiotics for a
shorter period than the study population, but otherwise, no
differences in either baseline characteristics or outcomes were
observed. Further, in a subset of patients, the last measurement
of some biomarkers was performed several days before dis-
charge, which could limit the reproducibility of our results. No
changes in associations were, however, observed when the
statistical analysis was restricted to patients who had all
biomarkers measured within 3 days of discharge. Second, as
we were limited to data which could be obtained from patient
records, we could not evaluate the effect of some potential risk
factors of readmission, including alcohol abuse, clinical sta-
bility on discharge, and discharge dispositions. Such factors
could potentially confound our results. Third, we cannot ac-
count for inappropriate antibiotic treatment, which could be a
risk factor for readmission. However, to our knowledge, no
previous studies have found that inappropriate antibiotic treat-
ment is associated with increased risk of readmission after
CAP. Fourth, this cohort was based on patients hospitalized
Fig. 2 Cumulative incidence curves by biomarker at discharge. Abbreviations: WBC white blood cells, CRP C-reactive protein
Fig. 3 Cumulative incidence
curve by number of risk factors.
Risk factors were WBC ≥
10.6 cells × 109/L and albumin <
32 g/L at discharge and the
presences of ≥ 2 co-morbidities.
Due to missing values, a total of
1139 patients were used in the
analysis
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between January 2011 and July 2012, and both demographic
characteristics and guidelines of treatment of pneumonia
could have changed since then, which might limit the gener-
alizability of our results.
Strengths
The main strength of this study was that we were able to
include all consecutive patients with x-ray-confirmed CAP
for a full 18 months, thus reducing the risk of inclusion bias.
Further, this study was multi-center, and the three hospitals
from where patients were included supported an entire region
in Denmark. We also had robust and almost complete data
regarding death, readmission, and causes of readmission,
due to access The Danish National Patient Register and The
Danish Civil Registration System.
Conclusions
In this study, we showed that discharge concentrations of
WBC ≥ 10.6 cells × 109/L and albumin < 32 g/L and the pres-
ences of ≥ 2 co-morbidities were associated with an increase
in risk of 30-day readmission for patients hospitalized for
CAP. The combination of biomarkers at discharge and co-
morbidities could be used to stratify patients according to risk
of readmission, and thus help guide post-discharge interven-
tions. However, due to the retrospective design of this study,
our results should be validated.
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